Orlando

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease2 trials
• Depression2 trials
• Schizophrenia2 trials
• Bipolar disorder1 trial
• Macular degeneration1 trial
• Parkinson disease1 trial

Phase

• Phase 34 trials
• Phase 23 trials

Status

• Completed5 trials
• Enrolling by invitation1 trial
• Recruiting1 trial

Lead sponsor

• Intra-Cellular Therapies, Inc.4 trials
• MapLight Therapeutics2 trials
• Outlook Therapeutics, Inc.1 trial

Running trials

• Enrolling by invitation

  An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

  NCT07459660· Phase 2· MapLight Therapeutics· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

  NCT06887192· Phase 2· MapLight Therapeutics· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• Schizophrenia2 recruiting

Closed trials

• Completed

  Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

  NCT06462586· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Completed

  A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

  NCT06190093· Phase 3· Outlook Therapeutics, Inc.· Source

• Completed

  Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

  NCT05766813· Phase 2· Intra-Cellular Therapies, Inc.· Source

• Completed

  An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05061719· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Completed

  Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT04985942· Phase 3· Intra-Cellular Therapies, Inc.· Source